Cyanocobalamin
drugOn this page
Also known as AntipernicinBehepanBerubigenBetalin 12CalomistCianocobalaminaCobaviteCyanocobalamin component of depinarCyanocobalamin component of dicopac kitCyanocobalamin component of vitapedCyanocobalamineCyanocobalaminumCyanocobalminCyanovit-b12CyominCytaconCytamenDodecaviteDodex
Summary
Cyanocobalamin (CHEMBL2110563) is an approved small molecule (ATC B03BA51); indicated across 48 conditions including iron deficiency anemia and anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: B03BA51 (+1 more)
- Indications: 48 conditions
- Clinical trials: 100
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2110563 |
| Name | Cyanocobalamin |
| Type | Small molecule |
| Max phase | 4 |
| ATC | B03BA51, B03BA01 |
Also known as: Antipernicin, Behepan, Berubigen, Betalin 12, Calomist, Cianocobalamina, Cobavite, Cyanocobalamin, Cyanocobalamin component of depinar, Cyanocobalamin component of dicopac kit, Cyanocobalamin component of vitaped, Cyanocobalamine
Parent form; salt/anhydrous children: CHEMBL2096655, CHEMBL2104118, CHEMBL2104381
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
48 indications (9 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| iron deficiency anemia | 4 | MONDO:0001356 | HP:0001891 |
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| chronic kidney disease | 4 | MONDO:0005300 | EFO:0003884 |
| osteoporosis | 4 | MONDO:0005298 | EFO:0003882 |
| vitamin B deficiency | 4 | MONDO:0042976 | MONDO:0042976 |
| type 2 diabetes mellitus | 4 | MONDO:0005148 | MONDO:0005148 |
| psoriasis | 3 | MONDO:0005083 | EFO:0000676 |
| psychotic disorder | 3 | MONDO:0005485 | EFO:0005407 |
| Alzheimer disease | 3 | MONDO:0004975 | MONDO:0004975 |
| amyotrophic lateral sclerosis | 3 | MONDO:0004976 | MONDO:0004976 |
| premature ejaculation | 3 | MONDO:0001780 | EFO:0803321 |
| brain injury | 3 | MONDO:0043510 | MONDO:0043510 |
| vitamin B12 deficiency | 2 | MONDO:0020696 | EFO:0000734 |
| autism | 2 | MONDO:0005260 | EFO:0003758 |
| nasopharyngeal neoplasm | 2 | MONDO:0005375 | EFO:0004252 |
| peripheral T-cell lymphoma, not otherwise specified | 2 | MONDO:0004964 | EFO:0000211 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| mesothelioma | 2 | MONDO:0005065 | EFO:0000588 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| heart failure | 2 | MONDO:0005252 | EFO:0003144 |
| atherosclerosis | 2 | MONDO:0005311 | EFO:0003914 |
| upper aerodigestive tract neoplasm | 2 | MONDO:0005398 | EFO:0004284 |
| head and neck cancer | 2 | MONDO:0005627 | EFO:0006859 |
| breast carcinoma | 2 | MONDO:0004989 | EFO:0000305 |
| myocardial infarction | 2 | MONDO:0005068 | EFO:0000612 |
| myocardial ischemia | 2 | MONDO:0024644 | EFO:1001375 |
| diabetic neuropathy | 2 | MONDO:0006626 | EFO:1000783 |
| lung neoplasm | 2 | MONDO:0021117 | MONDO:0008903 |
| depressive disorder | 2 | MONDO:0002050 | MONDO:0002050 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| heart disorder | 2 | MONDO:0005267 | EFO:0003777 |
| primary cutaneous T-cell non-Hodgkin lymphoma | 1 | MONDO:0000607 | EFO:0002913 |
| anaplastic large cell lymphoma | 1 | MONDO:0020325 | EFO:0003032 |
| Sezary syndrome | 1 | MONDO:0017844 | EFO:1000785 |
| mycosis fungoides | 1 | MONDO:0009691 | EFO:1001051 |
| peritoneal neoplasm | 1 | MONDO:0006901 | MONDO:0002087 |
| fallopian tube neoplasm | 1 | MONDO:0021092 | MONDO:0002158 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
| pulmonary alveolar proteinosis | 1 | MONDO:0001437 | MONDO:0001437 |
8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 100.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 44 |
| PHASE2 | 21 |
| PHASE4 | 11 |
| PHASE3 | 8 |
| PHASE2/PHASE3 | 5 |
| PHASE1/PHASE2 | 5 |
| PHASE1 | 5 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07029698 | PHASE4 | RECRUITING | A Study to See if a Combination of Vitamins That is Injected Into a Muscle is as Good and Safe as a Vitamin That is Taken by Mouth |
| NCT00164970 | PHASE4 | COMPLETED | Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia? |
| NCT00326833 | PHASE4 | UNKNOWN | How Many Patients Are in Need of Vitamin B12 Injections? |
| NCT01500785 | PHASE4 | TERMINATED | Intracoronary Administration of Levosimendan in Cardiac Surgery Patients |
| NCT01832129 | PHASE4 | COMPLETED | Vitamin B12 Acceptance and Biomarker Response Study |
| NCT02031289 | PHASE4 | COMPLETED | Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. |
| NCT02120274 | PHASE4 | TERMINATED | Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C |
| NCT02457507 | PHASE4 | COMPLETED | Vitamin B12 Supplement to Prevent Cognitive Decline |
| NCT03522428 | PHASE4 | COMPLETED | Vitamin B12 Pregnancy Supplementation |
| NCT04387201 | PHASE4 | COMPLETED | GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response |
| NCT05221892 | PHASE4 | COMPLETED | Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo |
| NCT05005897 | PHASE2/PHASE3 | RECRUITING | Early Infant Micronutrition and Development |
| NCT06966856 | PHASE3 | NOT_YET_RECRUITING | This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcting Early-onset Vitamin B12 Deficiency in Adult Patients Using Proton Pump Inhibitors (PPIs). The Primary Outcome is the Change in Serum Vitamin B12 Levels Over a 6-week |
| NCT00004734 | PHASE3 | COMPLETED | Vitamin Therapy for Prevention of Stroke |
| NCT00056225 | PHASE3 | COMPLETED | VITAL - VITamins to Slow ALzheimer’s Disease (Homocysteine Study) |
| NCT00114400 | PHASE2/PHASE3 | COMPLETED | BVAIT: B-Vitamin Atherosclerosis Intervention Trial |
| NCT00350116 | PHASE3 | COMPLETED | Topical Vitamin B12 in Chronic Plaque Psoriasis |
| NCT00659269 | PHASE3 | COMPLETED | A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients |
| NCT01795131 | PHASE2/PHASE3 | COMPLETED | Vitamin B12 Supplementation During Pregnancy |
| NCT02272842 | PHASE2/PHASE3 | UNKNOWN | Vitamin B12, Neurodevelopment and Growth in Nepal |
| NCT02786823 | PHASE2/PHASE3 | COMPLETED | Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes |
| NCT03349333 | PHASE3 | COMPLETED | A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL |
| NCT04085354 | PHASE3 | COMPLETED | Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation |
| NCT05958277 | PHASE3 | COMPLETED | Vitamin B12 vs B3 for Nerve Regeneration and Functional Recovery After Pediatric Traumatic Brain Injury |
| NCT00000541 | PHASE2 | COMPLETED | Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFACS) |
| NCT00216099 | PHASE2 | COMPLETED | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer |
| NCT00227019 | PHASE2 | COMPLETED | Phase 2 Trial of Bevacizumab in Combination With Pemetrexed |
| NCT00243022 | PHASE2 | TERMINATED | Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme |
| NCT00402883 | PHASE2 | TERMINATED | Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer |
| NCT00481871 | PHASE1/PHASE2 | COMPLETED | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies |
| NCT00541073 | PHASE2 | COMPLETED | Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery |
| NCT00606502 | PHASE2 | COMPLETED | Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment |
| NCT00609518 | PHASE2 | COMPLETED | A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer |
| NCT00717730 | PHASE2 | COMPLETED | Folic Acid and Vitamin B12 in Young Indian Children |
| NCT00722553 | PHASE2 | COMPLETED | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder |
| NCT00923273 | PHASE1/PHASE2 | TERMINATED | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer |
| NCT00998946 | PHASE2 | COMPLETED | Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma |
| NCT01057589 | PHASE2 | COMPLETED | A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer |
| NCT01118624 | PHASE2 | COMPLETED | Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer |
| NCT01165021 | PHASE2 | COMPLETED | A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).